Immunoqure Ag

Fit Biotech Oyj Plc

Fit Biotech Oy

Valipharma

Helsingin Yliopiston Rahastot

Kai Krohn

Annalisa Macagno

Adrian Hayday

Kai Kisand

Annamari Ranki

Mike Rothe

Shimobi Onuoha

Paert Peterson

Martin Woodward

Syeda F Y Haque

Part Peterson

Edward Stuart

Andres Männik

Mart Ustav

Urve Toots

Ene Ustav

Vesna Blazevic

Steffen Meyer

Marja Tähtinen

Philip Vlaicu

Leena Karenko

Sonja Hahtola

Päivi Peltomäki

Pärt Peterson

Wael University Of Sharjah Hassan

Emilia Carlsson

Kristian Ovaska

Sampsa Hautaniemi

Markku Helle

Valtteri Häyry

Syeda F Haque

Andres Mannik

Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-α antibodies as well as IFN-α binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Human anti-IFN-α antibodies

Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.

CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody

Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-&#x3b1; antibodies as well as IFN-&#x3b1; binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Human anti-IFN-&#x3b1; antibodies

Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.

Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F

Nucleic acid molecules encoding monoclonal antibodies specific for IL-22

Human anti-IL-32 antibodies and methods of making and using the same

Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.

Method of isolating human antibodies

A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.

Methods of treating HIV diseases using novel expression vectors

Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F

The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing the vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of the vectors. The novel vectors comprise (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. The vectors lack a papilloma virus origin of replication.

Expression vectors and uses thereof

The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising an expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of binding to a nuclear component and a multimerized DNA sequence forming a binding site for the nuclear-anchoring protein, and optionally an expression cassette of a gene, genes or a DNA sequence or DNA sequences of interest. The present invention further relates to DNA vaccines and gene therapeutics containing the novel vectors, to methods for the preparation of the novel vectors and the DNA vaccines and gene therapeutics.

Growing community of inventors

Salmentaka, Finland

Kai Krohn